Denali Therapeutics Inc. DNLI EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s EPS (diluted)?
- Denali Therapeutics Inc. (DNLI) reported EPS (diluted) of -$0.69 in Q1 2026.
- How has Denali Therapeutics Inc.'s EPS (diluted) changed year-over-year?
- Denali Therapeutics Inc.'s EPS (diluted) increased by 11.5% year-over-year, from -$0.78 to -$0.69.
- What is the long-term trend for Denali Therapeutics Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Denali Therapeutics Inc.'s EPS (diluted) has grown at a 5.6% compound annual growth rate (CAGR), from -$2.39 to -$2.97.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.